296 related articles for article (PubMed ID: 34723980)
1. Role of the IL-33/ST2 axis in cardiovascular disease: A systematic review and meta-analysis.
Sun Y; Pavey H; Wilkinson I; Fisk M
PLoS One; 2021; 16(11):e0259026. PubMed ID: 34723980
[TBL] [Abstract][Full Text] [Related]
2. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
[TBL] [Abstract][Full Text] [Related]
3. ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans.
Pusceddu I; Dieplinger B; Mueller T
Clin Chim Acta; 2019 Aug; 495():493-500. PubMed ID: 31136737
[TBL] [Abstract][Full Text] [Related]
4. The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-analysis.
Liu N; Hang T; Gao X; Yang W; Kong W; Lou Q; Yang J
PLoS One; 2020; 15(9):e0238775. PubMed ID: 32886697
[TBL] [Abstract][Full Text] [Related]
5. Conflicting vascular and metabolic impact of the IL-33/sST2 axis.
Altara R; Ghali R; Mallat Z; Cataliotti A; Booz GW; Zouein FA
Cardiovasc Res; 2018 Oct; 114(12):1578-1594. PubMed ID: 29982301
[TBL] [Abstract][Full Text] [Related]
6. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome.
Demyanets S; Speidl WS; Tentzeris I; Jarai R; Katsaros KM; Farhan S; Krychtiuk KA; Wonnerth A; Weiss TW; Huber K; Wojta J
PLoS One; 2014; 9(4):e95055. PubMed ID: 24751794
[TBL] [Abstract][Full Text] [Related]
7. The Interleukin-33/ST2 Pathway Is Expressed in the Failing Human Heart and Associated with Pro-fibrotic Remodeling of the Myocardium.
Tseng CCS; Huibers MMH; van Kuik J; de Weger RA; Vink A; de Jonge N
J Cardiovasc Transl Res; 2018 Feb; 11(1):15-21. PubMed ID: 29285671
[TBL] [Abstract][Full Text] [Related]
8. Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study.
Pfetsch V; Sanin V; Jaensch A; Dallmeier D; Mons U; Brenner H; Koenig W; Rothenbacher D
Cardiovasc Drugs Ther; 2017 Apr; 31(2):167-177. PubMed ID: 28283847
[TBL] [Abstract][Full Text] [Related]
9. Predicting long-term cardiovascular outcomes of patients with acute myocardial infarction using soluble ST2.
Somuncu MU; Kalayci B; Avci A; Akgun T; Karakurt H; Demir AR; Avci Y; Can M
Horm Mol Biol Clin Investig; 2020 Feb; 41(2):. PubMed ID: 32112700
[TBL] [Abstract][Full Text] [Related]
10. IL-33/ST2 signaling pathway and Alzheimer's disease: A systematic review and meta-analysis.
Jiang T; Zheng T; Li W; Liu N; Wang M
Clin Neurol Neurosurg; 2023 Jul; 230():107773. PubMed ID: 37172376
[TBL] [Abstract][Full Text] [Related]
11. Soluble ST2 in Patients with Carotid Artery Stenosis-Association with Plaque Morphology and Long-Term Outcome.
Stojkovic S; Kampf S; Harkot O; Nackenhorst M; Brekalo M; Huber K; Hengstenberg C; Neumayer C; Wojta J; Demyanets S
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240352
[TBL] [Abstract][Full Text] [Related]
12. Dysfunctional EAT thickness may promote maladaptive heart remodeling in CVD patients through the ST2-IL33 system, directly related to EPAC protein expression.
Vianello E; Dozio E; Bandera F; Schmitz G; Nebuloni M; Longhi E; Tacchini L; Guazzi M; Corsi Romanelli MM
Sci Rep; 2019 Jul; 9(1):10331. PubMed ID: 31316160
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-33 and Soluble ST2 Levels in Infants with Hypoxic-Ischemic Encephalopathy.
Hamano H; Takahashi K; Kimura S; Matsuguma C; Kaneyasu H; Fujimoto Y; Ohta N; Okada S; Hasegawa S
Neonatology; 2023; 120(3):353-362. PubMed ID: 36996771
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary Production of Soluble ST2 in Heart Failure.
Pascual-Figal DA; Pérez-Martínez MT; Asensio-Lopez MC; Sanchez-Más J; García-García ME; Martinez CM; Lencina M; Jara R; Januzzi JL; Lax A
Circ Heart Fail; 2018 Dec; 11(12):e005488. PubMed ID: 30562096
[TBL] [Abstract][Full Text] [Related]
15. Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress.
Veeraveedu PT; Sanada S; Okuda K; Fu HY; Matsuzaki T; Araki R; Yamato M; Yasuda K; Sakata Y; Yoshimoto T; Minamino T
Biochem Pharmacol; 2017 Aug; 138():73-80. PubMed ID: 28450225
[TBL] [Abstract][Full Text] [Related]
16. Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects.
Cardellini M; Rizza S; Casagrande V; Cardolini I; Ballanti M; Davato F; Porzio O; Canale MP; Legramante JM; Mavilio M; Menghini R; Martelli E; Farcomeni A; Federici M
Acta Diabetol; 2019 Mar; 56(3):273-280. PubMed ID: 30259114
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-33/ST2 Axis as Potential Biomarker and Therapeutic Target in Kawasaki Disease.
Okada S; Yasudo H; Ohnishi Y; Matsuguma C; Fukano R; Motonaga T; Waniishi T; Hasegawa S
Inflammation; 2023 Feb; 46(1):480-490. PubMed ID: 36208354
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Value of sST2 in Cardiovascular Diseases: A Systematic Review and Meta-Analysis.
Zhang T; Xu C; Zhao R; Cao Z
Front Cardiovasc Med; 2021; 8():697837. PubMed ID: 34368254
[TBL] [Abstract][Full Text] [Related]
19. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality.
Hughes MF; Appelbaum S; Havulinna AS; Jagodzinski A; Zeller T; Kee F; Blankenberg S; Salomaa V;
Heart; 2014 Nov; 100(21):1715-21. PubMed ID: 25080471
[TBL] [Abstract][Full Text] [Related]
20. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial.
Kohli P; Bonaca MP; Kakkar R; Kudinova AY; Scirica BM; Sabatine MS; Murphy SA; Braunwald E; Lee RT; Morrow DA
Clin Chem; 2012 Jan; 58(1):257-66. PubMed ID: 22096031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
